AbbVie is a global biopharmaceutical company headquartered in North Chicago, Illinois, with a dedicated neuroscience research division focused on developing novel therapies for neurodegenerative diseases. The company's neuroscience program encompasses a broad portfolio targeting Alzheimer's disease, Parkinson's disease, Progressive Supranuclear Palsy (PSP), and other movement disorders. AbbVie spun off from Abbott Laboratories in 2013 and has since become one of the largest pharmaceutical companies globally.
| Attribute | Details |
|---|---|
| Headquarters | North Chicago, Illinois, USA |
| Founded | 2013 (spun off from Abbott Laboratories) |
| Market Cap | One of the largest pharmaceutical companies globally |
| R&D Focus | Immunology, Oncology, Neuroscience, Virology |
| Employees | 50,000+ worldwide |
| Revenue | $56+ billion annually |
AbbVie's neuroscience division is driven by the mission to:
AbbVie's neuroscience division focuses on several key therapeutic areas:
AbbVie is developing tau aggregation inhibitors and anti-tau immunotherapies targeting the pathological tau proteins that accumulate in PSP and Alzheimer's disease. These approaches aim to slow or halt disease progression by preventing tau propagation between neurons.
Research programs target the aggregation of alpha-synuclein protein, which is central to Parkinson's disease and Dementia with Lewy Bodies. AbbVie has investigated small molecules and antibodies designed to prevent toxic oligomer formation.
The company is exploring therapeutic approaches targeting neuroinflammation, a common feature of neurodegenerative diseases. This includes microglial modulators and cytokine pathway inhibitors.
AbbVie prioritizes therapies that modify the underlying disease process rather than merely treating symptoms, with a focus on early intervention and biomarker-driven patient selection.
AbbVie has advanced tau aggregation inhibitors into clinical development, targeting the microtubule-binding domain of tau protein. These small molecules are designed to prevent tau fibril formation and spread.
Monoclonal antibodies targeting pathological tau are in various stages of clinical development. These immunotherapies aim to clear tau aggregates from the brain or prevent their formation.
AbbVie invests in biomarker development to:
AbbVie has conducted and continues to conduct clinical trials in PSP, working with leading movement disorder centers globally to evaluate novel therapeutic candidates.
AbbVie has participated in multiple clinical trials for neurodegenerative diseases, including:
AbbVie collaborates with:
AbbVie's neuroscience pipeline includes:
AbbVie allocates substantial resources to neuroscience R&D, with annual investments in neurodegenerative disease research exceeding $500 million. The company has expanded its neuroscience footprint through both internal development and strategic partnerships, including acquisitions and licensing agreements.
Tau Pipeline Advancement: Advanced multiple tau aggregation inhibitors into clinical development phases
Clinical Trial Network: Established partnerships with over 50 global clinical trial sites for neurodegenerative disease research
Biomarker Development: Contributed to development of tau and neurofilament light chain (NfL) biomarkers for patient selection and disease monitoring
PSP Clinical Program: Conducted Phase I/II trials in PSP, contributing to understanding of tau-targeted therapies
Publication Record: Published numerous peer-reviewed articles in top neuroscience journals
Regulatory Engagement: Worked with FDA and EMA on regulatory pathways for tau-targeted therapies
AbbVie is actively involved in PSP research and drug development:
AbbVie works with: